Progressive Grey Matter Volume Changes in Patients with Schizophrenia over 6 Weeks of Antipsychotic Treatment and Their Relationship to Clinical Improvement

Neuroscience Bulletin
Xiao ZhangHao Yan

Abstract

Cross-sectional and longitudinal studies have identified widespread and progressive grey matter volume (GMV) reductions in schizophrenia, especially in the frontal lobe. In this study, we found a progressive GMV decrease in the rostral medial frontal cortex (rMFC, including the anterior cingulate cortex) in the patient group during a 6-week follow-up of 40 patients with schizophrenia and 31 healthy controls well-matched for age, gender, and education. The higher baseline GMV in the rMFC predicted better improvement in the positive score on the Positive and Negative Syndrome Scale (PANSS), and this might be related to the improved reality-monitoring. Besides, a higher baseline GMV in the posterior rMFC predicted better remission of general symptoms, and a lesser GMV reduction in this region was correlated with better remission of negative symptoms, probably associated with ameliorated self-referential processing and social cognition. Besides, a shorter disease course and higher educational level contributed to better improvement in the general psychopathological PANSS score, and a family history was negatively associated with improvement of the negative and total PANSS scores. These phenomena might be important for understanding...Continue Reading

References

Jun 8, 1999·Archives of General Psychiatry·J M GoldsteinM T Tsuang
Mar 22, 2001·Proceedings of the National Academy of Sciences of the United States of America·D A GusnardM E Raichle
May 10, 2001·Schizophrenia Research·M E ShentonR W McCarley
Jun 30, 2001·The American Journal of Psychiatry·W G StaalR S Kahn
Oct 16, 2004·Science·K Richard RidderinkhofSander Nieuwenhuis
Oct 4, 2005·Journal of Cognitive Neuroscience·Jason P MitchellC Neil Macrae
Nov 1, 2005·Psychiatry Research·Konasale M R PrasadMatcheri S Keshavan
Jan 18, 2006·Schizophrenia Research·Ragy R GirgisAntonio Y Hardan
Mar 23, 2006·Nature Reviews. Neuroscience·David M Amodio, Chris D Frith
Sep 1, 2007·NeuroImage·John Ashburner
Mar 7, 2008·Cerebral Cortex·Sophia VinogradovGregory V Simpson
Mar 11, 2008·Neuropsychologia·Martin BrüneMartin Tegenthoff
May 23, 2008·Schizophrenia Bulletin·Michael F Green, David I Leitman
Jun 11, 2008·European Psychiatry : the Journal of the Association of European Psychiatrists·L BurkeS Frangou
Aug 19, 2008·The American Journal of Psychiatry·Melissa FisherSophia Vinogradov
Jan 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Susan Whitfield-GabrieliLarry J Seidman
Aug 4, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomas KasparekEva Ceskova
Jun 4, 2010·Social Cognitive and Affective Neuroscience·Cédric LemognePhilippe Fossati
Oct 7, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Marie BudaJon S Simons
Nov 15, 2011·Schizophrenia Bulletin·Simone Kühn, Jürgen Gallinat
Oct 9, 2012·Schizophrenia Bulletin·Sander V HaijmaRené S Kahn
Nov 18, 2015·Nature Communications·Jane R GarrisonJon S Simons
Jan 19, 2016·Lancet·Michael J OwenPreben B Mortensen
Apr 15, 2016·Neuroinformatics·Chao-Gan YanYu-Feng Zang

❮ Previous
Next ❯

Software Mentioned

Statistical Package for the Social Sciences
DPABI
SPM12
MatLab
SPM
DARTEL

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here